LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 381.37K shares, a 1042.56% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 200.54K shares, a 137.31% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 163.41K shares, a 474.50% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 343.79K shares, a 8.20% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 625.07K shares.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 137.58K shares, a 41.04% decline from fiscal 2022.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 233.36K shares, a 1481.22% increase from fiscal 2021.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 14.76K shares, a 83.86% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 381.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 1.09M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 200.54K shares 10-Q · filed 2026-05-11 | 741.11K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 163.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 625.07K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 343.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 490.11K shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 33.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 464.05K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 84.50K shares 10-Q · filed 2025-05-08 | 441.35K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 28.44K shares derived: 8-K 12 month − 10-Q 9 month · filed 2025-05-08 | 380.10K shares 8-K · filed 2025-05-08 |
| 2024-09-30 | 317.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 371.90K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 10.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 139.89K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 23.25K shares 10-Q · filed 2024-05-13 | 139.38K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 20.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 137.58K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 85.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 157.35K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 10.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 121.08K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 21.45K shares 10-Q · filed 2023-05-08 | 111.51K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 40.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | 233.36K shares 10-K · filed 2023-03-20 |
| 2022-09-30 | 49.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 207.47K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 594.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 158.03K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 143.30K shares 10-Q · filed 2022-05-12 | 157.43K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 14.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 14.76K shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2021-03-31 | 623.00 shares 10-Q · filed 2021-05-13 | |
| 2020-12-31 | 91.41K shares 10-K · filed 2022-03-17 | |
| 2019-12-31 | 32.33K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |